Fortrea Holdings Inc. (FTRE)vsBeiGene, Ltd. (ONC)
FTRE
Fortrea Holdings Inc.
$17.20
+1.06%
HEALTHCARE · Cap: $1.60B
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 129% more annual revenue ($6.13B vs $2.68B). ONC leads profitability with a 10.7% profit margin vs -3.2%. FTRE appears more attractively valued with a PEG of 0.34. ONC earns a higher WallStSmart Score of 64/100 (C+).
FTRE
Hold40
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-41.2%
Fair Value
$8.21
Current Price
$17.20
$8.99 premium
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 2.6%
Weak financial health signals
ROE of -85.0% — below average capital efficiency
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : FTRE
The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : FTRE
The primary concerns for FTRE are Market Cap, Operating Margin, Piotroski F-Score. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
FTRE profiles as a turnaround stock while ONC is a growth play — different risk/reward profiles.
FTRE carries more volatility with a beta of 1.95 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 40/100) and 29.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortrea Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?